These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 7705868)
21. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870 [TBL] [Abstract][Full Text] [Related]
22. [Clinically apparent liver damage during brief tuberculosis therapy]. Estay S; Armas Merino R; Vega C; Soto JR Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017 [No Abstract] [Full Text] [Related]
23. Antituberculous therapy and acute liver function. Bourke SJ; White J; Stenton SC; Hendrick DJ Lancet; 1995 May; 345(8958):1171-2. PubMed ID: 7786347 [No Abstract] [Full Text] [Related]
24. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961 [TBL] [Abstract][Full Text] [Related]
25. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759 [TBL] [Abstract][Full Text] [Related]
27. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900 [TBL] [Abstract][Full Text] [Related]
28. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622 [TBL] [Abstract][Full Text] [Related]
29. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence]. Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667 [TBL] [Abstract][Full Text] [Related]
30. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Aranda FM; Frías A; Visca M; Aidar O; Perés S; de Larrañaga GF J Gastroenterol Hepatol; 2013 Feb; 28(2):323-8. PubMed ID: 23190413 [TBL] [Abstract][Full Text] [Related]
31. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203 [TBL] [Abstract][Full Text] [Related]
32. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127 [TBL] [Abstract][Full Text] [Related]
33. Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats. Srivastava RK; Sharma S; Verma S; Arora B; Lal H Methods Find Exp Clin Pharmacol; 2008 Dec; 30(10):731-7. PubMed ID: 19271021 [TBL] [Abstract][Full Text] [Related]
37. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions. Vu D; Macdonald L CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338 [No Abstract] [Full Text] [Related]
38. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069 [TBL] [Abstract][Full Text] [Related]
39. [Synergistic effect of rifampicin on hepatotoxicity of isoniazid]. Skakun NP; Shman'ko VV Antibiot Med Biotekhnol; 1985 Mar; 30(3):185-9. PubMed ID: 4015060 [TBL] [Abstract][Full Text] [Related]
40. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection. Garca-Doval I J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]